Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • CML • Hematology • Journal Club ft. NEJM publications
What factors do you consider when choosing between asciminib vs TKI in a newly diagnosed CML patient?
Will you start using asciminib for all? Or are there certain patient or disease factors where you would still select TKI therapy?
Answer from: Medical Oncologist at Community Practice
I think any patient is a good candidate for asciminib, with the exception of those with atypical transcripts (e.g., b2a3, b3a3). The decision would mostly depend on the goals of the patient and the availability and access. Asciminib is particularly well suited for patients who would be interested in...
Sign in or Register to read more
Answer from: at Academic Institution
Despite the good tolerability and efficacy of asciminib, I do not use asciminib in all patients. For some patients, insurance may deny its use first or second line. Imatinib is generic, low-cost, and has an excellent long-term safety profile. It can be a good choice for older patients and patients w...
Answer from: at Academic Institution
The data for the ASC4FIRST study is fairly compelling- improved response and tolerability, explaining why the FDA approved and the NCCN endorsed asciminib for front-line use. Based on my experience over >10 years working on its development and these data, I would discuss and advise asciminib for ...